The global pediatric drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to fuel the market growth include a rise in the birth rate along with the increased volume of fatal pediatric cases, which are leading to even mortality due to various diseases, viral infections, gastrointestinal disorders, lung cancers and malnutrition every year. For instance, in 2018, The Global Health Observatory (GHO) published the fact sheet for the leading causes of child mortality. According to the estimates from 2017, Diarrhea is the leading cause of mortality among children, and neonatal mortalities accounted for 47% of mortalities among children under age five which in turn, requires efficient treatment, thereby driving the market growth.

Moreover, the rise in prevalence of renal or pulmonary dysfunctions following hematopoietic stem-cell transplantations (HSCT) due to defective or low immunity is another major factor that is anticipated to boost the growth of the market during the forecast period. Pediatric medicine is a branch of medicine that deals with the medical care, their development and related diseases of infants, children, and adolescents. The pediatric drugs market grows significantly as children often suffer from gastrointestinal, allergic, respiratory, and other chronic diseases owing to their lower immunity. In addition, in order to maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in April 2019, GlaxoSmithKline plc received approval from the US Food and Drug Administration (FDA) for its intravenous (IV) Benlysta (belimumab), the first medicine in the US approved for children with systemic lupus erythematosus (SLE) from as young as five years of age cranial defects and consolidate their market positions across the globe. 

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Drug Type 

o By Route of Administration

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape: Johnson & Johnson Services, Inc., Novartis International AG, and F. Hoffman La-Roche AG, among others. 

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Pediatric Drugs Market Report by Segment

By Drug Type

    • Respiratory Disorder Drugs

    • Autoimmune Disorder Drugs

    • Gastrointestinal Drugs

    • CVD Drugs

    • Others

By Route of Administration

    • Oral

    • Topical

    • Parenteral

    • Others

Global Pediatric Drugs Market by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa